SCHOFIELD, Wis., April 24, 2012 /PRNewswire/ -- PuraMed BioScience, Inc.® (OTC Bulletin Board: PMBS), the producer of over-the-counter medicinal and healthcare products, has implemented an aggressive public awareness campaign to promote LipiGesic M in the retail sector with major campaigns planned in May and June to promote sales at both Walgreens and CVS/pharmacy stores.
LipiGesic M is a unique, homeopathic formulation of feverfew and ginger that is delivered sublingually (under the tongue). This method of delivery allows the absorption of full-strength active ingredients directly into the bloodstream for effective and fast results. Many users report feelings of relief within minutes of taking the medication.
"We are ramping up flights of our radio endorsement and placements of newspaper advertisements to target key metropolitan areas to create awareness of LipiGesic M and expand retail sales," says PuraMed BioScience CEO Russell Mitchell. "We have implemented a manufacturer's coupon campaign as an added incentive for migraine sufferers to try LipiGesic M as affordable and effective relief from migraine."
PuraMed BioScience has also invested in efforts to build the awareness of: pharmacists through advertisements placed in Pharmacy Times magazine; health care providers by attendance at key medical conferences, including National Headache Foundation events; headache specialists and headache sufferers through advertisements placed in Headwise magazine; and the general public through expert interviews featured on local news programs in key markets around the country.
A team of third-party experts has also supported LipiGesic M in various media venues. Medical researcher and headache expert, Roger Cady, MD, mentioned LipiGesic in an article by Fox News http://www.foxnews.com/health/2012/04/11/5-natural-headache-remedies/. LipiGesic M also has endorsements from holistic pharmacist, author and lecturer, Sherry Torkos, B.Sc, Phm; and fitness and nutrition expert, J. J. Virgin. These efforts along with presence on social media channels are designed to support the retail expansion of LipiGesic M.
"We are pleased with the response that we have received from the medical community," says Mitchell. "We look forward to letting the public know that there is a clinically-tested, over-the-counter medication that is an effective and affordable treatment for migraine."
In a clinical study conducted by leading headache researcher Dr. Roger Cady, LipiGesic M was shown to reduce or eliminate migraine pain in 63 percent of occurrences at two hours post dose. The findings of this clinical trial were published in the July 2011 issue of Headache: The Journal of Head and Face Pain, a top-tier medical journal of the American Headache Society*. The study also concluded that LipiGesic M's proprietary formula of feverfew and ginger appears to be a safe and effective first-line treatment when taken at the onset of migraine.
For additional information on LipiGesic M, visit www.LipiGesicM.com.
*Cady RK, Goldstein J, Nett R, et al. A Double-Blind Placebo-Controlled Pilot study of (LipiGesic® M) Sublingual Feverfew and Ginger in the Treatment of Migraine. Headache: The Journal of Head and Face Pain. 2011; 51:1078-1086
About PuraMed BioScience, Inc.®:
PuraMed BioScience, Inc.® engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic® M, which provides acute relief from migraine headaches. PuraMed BioScience also has plans to launch LipiGesic PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic H for tension-type headaches. For more information on PuraMed, visit the Company website at www.PuraMedBioScience.com, join the Company's group page on Facebook by searching "PuraMed BioScience" and follow the Company on Twitter at www.twitter.com/puramed.
Forward Looking Statements:
This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
For more information, contact:
Russell Mitchell, Chairman and CEO
PuraMed BioScience, Inc.
SOURCE PuraMed BioScience, Inc.